Accurate detection of Neisseria gonorrhoeae ciprofloxacin susceptibility directly from genital and extragenital clinical samples: towards genotype-guided antimicrobial therapy. by Pond, MJ et al.
Accurate detection of Neisseria gonorrhoeae ciprofloxacin susceptibility
directly from genital and extragenital clinical samples: towards
genotype-guided antimicrobial therapy
Marcus J. Pond1, Catherine L. Hall1, Victoria F. Miari1, Michelle Cole2, Ken G. Laing1, Heena Jagatia1,
Emma Harding-Esch1,3, Irene M. Monahan1, Timothy Planche1,4, Jason Hinds1, Catherine A. Ison2,
Stephanie Chisholm2, Philip D. Butcher1 and Syed Tariq Sadiq1,3,5*
1Institute for Infection and Immunity, St George’s, University of London, London, UK; 2Sexually Transmitted Bacteria Reference Unit,
Public Health England, Colindale, London, UK; 3Department of STI/HIV, Public Health England, Colindale, London, UK; 4Medical
Microbiology, South West London Pathology, St George’s University Hospitals NHS Foundation Trust, London, UK; 5Department of
Genitourinary & HIV Medicine, St George’s University Hospitals NHS Foundation Trust, London, UK
*Corresponding author. Applied Diagnostic and Research Evaluation Unit, Institute for Infection and Immunity, St George’s, University of London,
London SW17 0RE, UK. Tel: +44-2087255740; Fax: +44-2087250137; E-mail: ssadiq@sgul.ac.uk
Received 10 September 2015; returned 30 September 2015; revised 11 November 2015; accepted 12 November 2015
Introduction: Increasing use of nucleic acid amplification tests (NAATs) as the primary means of diagnosing
gonococcal infection has resulted in diminished availability of Neisseria gonorrhoeae antimicrobial susceptibility
data. We conducted a prospective diagnostic assessment of a real-time PCR assay (NGSNP) enabling direct
detection of gonococcal ciprofloxacin susceptibility from a range of clinical sample types.
Methods: NGSNP, designed to discriminate an SNP associated with ciprofloxacin resistance within the
N. gonorrhoeae genome, was validated using a characterized panel of geographically diverse isolates (n¼90)
and evaluated to predict ciprofloxacin susceptibility directly on N. gonorrhoeae-positive NAAT lysates derived
from genital (n¼174) and non-genital (n¼116) samples (n¼290), from 222 culture-confirmed clinical episodes
of gonococcal infection.
Results: NGSNP correctly genotyped all phenotypically susceptible (n¼49) and resistant (n¼41) panel isolates.
Ciprofloxacin-resistant N. gonorrhoeae was responsible for infection in 29.7% (n¼66) of clinical episodes
evaluated. Compared with phenotypic susceptibility testing, NGSNP demonstrated sensitivity and specificity
of 95.8% (95% CI 91.5%–98.3%) and 100% (95% CI 94.7%–100%), respectively, for detecting ciprofloxacin-
susceptible N. gonorrhoeae, with a positive predictive value of 100% (95% CI 97.7%–100%). Applied to urogenital
(n¼164), rectal (n¼40) and pharyngeal samples alone (n¼30), positive predictive values were 100%
(95% CI 96.8%–100%), 100% (95% CI 87.2%–100%) and 100% (95% CI 82.4%–100%), respectively.
Conclusions: Genotypic prediction of N. gonorrhoeae ciprofloxacin susceptibility directly from clinical samples was
highly accurate and, in the absence of culture, will facilitate use of tailored therapy for gonococcal infection, sparing
use of current empirical treatment regimens and enhancing acquisition of susceptibility data for surveillance.
Introduction
Neisseria gonorrhoeae infection is frequently treated empirically at
the point of care (PoC), based on clinical presentation alongside
findings from microscopy of Gram-stained genital swabs.1
Efficacy of antimicrobial therapy is threatened by the development
of successive antimicrobial resistance (AMR) in response to anti-
biotic classes used over time,2 resulting in potentially empirically
untreatable gonorrhoea.3 In addition, nucleic acid amplification
tests (NAATs) have largely replaced culture as the primary labora-
tory method of gonorrhoea diagnosis,4,5 resulting in a decline in
availability of antibiotic susceptibility data to guide prescribing.6
These challenges have instigated the development of the WHO
Global action plan to control the spread and impact of AMR in
N. gonorrhoeae,7 recognizing the need for molecular methods
for monitoring and detecting AMR. Fluoroquinolones may
represent a favourable group of antimicrobials to which molecular
AMR detection may be applied due to the relative genetic simpli-
city of resistance, mediated predominantly through SNPs within
genes coding for the GyrA subunit of DNA gyrase and ParC subunit
of topoisomerase IV.8
Deployment of genotypic methods for the detection of AMR in
N. gonorrhoeae is potentially challenged by cross-reaction with
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commensal Neisseria species at extragenital sites, detrimentally
affecting assay specificity.9 The aim of this study was to ascertain
the diagnostic performance of a real-time PCR assay (NGSNP),
enabling genotypic prediction of ciprofloxacin-susceptible or
-resistant N. gonorrhoeae directly on clinical samples taken from
diverse sites. NGSNP functionality was verified using a geograph-
ically diverse gonococcal isolate panel and its capacity to genoty-
pically predict gonococcal fluoroquinolone susceptibility, directly
from residual NAAT samples, was evaluated through comparison
with routine antimicrobial susceptibility testing (AST).
Materials and methods
NGSNP real-time PCR assay
NGSNP was designed to discriminate an SNP occurring within the gyrA gene
of the gonococcal genome. This SNP was identified because of its well-
characterized association with phenotypic resistance to ciprofloxacin.8
Oligonucleotides were designed using Primer Express 3.0 software
(Life Technologies, Foster City, CA, USA). PCR primers were designed to
amplify a 77 bp region (nucleotide coordinates 620887–620954) of
gyrA (locus tag: NGO0629) of N. gonorrhoeae strain FA1090 (nucleotide
accession NC_002946.2). TaqMan hydrolysis probes (Life Technologies,
Paisley, UK) were designed to discriminate a cytosine to thymine SNP at
nucleotide position 620919 (see Table S1, available as Supplementary
data at JAC Online).
Real-time PCR reactions were performed in a final volume of 20 mL,
consisting of 10 mL of SsoFastTM Probes Supermix (Bio-Rad Laboratories,
Hemel Hempstead, UK) and 5 mL of extracted clinical sample or 0.1 ng
of bacterial genomic DNA. Final reaction primer and probe concentrations
are detailed in the Supplementary Methods. NGSNP reactions were per-
formed in duplicate using a CFX96 (Bio-Rad) real-time thermal cycler.
PCR thermocycling conditions were 958C for 5 min; 45 cycles of 958C for
15 s; 608C for 60 s. Real-time fluorescence detection was performed dur-
ing the 608C annealing/extension step of each cycle.
Post-PCR analysis of reaction fluorescence was performed using
Bio-Rad CFX Manager software version 3.0. Thresholds for reaction positiv-
ity were set at 2000 relative fluorescence units to background for both FAM
(510–530 nm) and VIC (560–580 nm) channels. Discrimination of geno-
types was conducted with horizontal (WT) and vertical (SNP) alleles set to
a Cq of 45. Three nucleic acid controls for real-time PCR runs were used at a
normalized concentration of 0.1 ng/mL each. These controls consisted of
nucleic acid from: strain FA1090 (WT with respect to antibiotic resistance);
strain SGUL_239 (a ciprofloxacin-resistant local isolate possessing the
base change at nucleotide position 620919 and having a ciprofloxacin
MIC of 32 mg/L); and an equimolar mixture of nucleic acid from both
these strains. Testing clinical and validation panels; SNP detection assays
were performed blinded to phenotypic susceptibility results.
Nationally representative ciprofloxacin-resistant
N. gonorrhoeae panel
Ciprofloxacin-resistant isolates (MIC.0.5 mg/L) with an associated STusing
N. gonorrhoeae multiantigen sequence typing (NG-MAST) archived between
2000–12 at the Sexually Transmitted Bacteria Reference Unit (STBRU), PHE,
as part of the UK Gonococcal Resistance to Antimicrobials Surveillance
Programme (GRASP) and European Gonococcal Antimicrobial Surveillance
Programme collections were identified to create a porB/tbpB phylogenetic-
ally diverse panel of isolates, circulating within the UK and Europe (see the
Supplementary Methods for culture methodology).
Locally representative N. gonorrhoeae panel
An additional panel of isolates was identified to provide indicative per-
formance within our local setting. Sixty-seven consecutively collected
isolates from St George’s University Hospitals NHS Foundation Trust
(SGH), submitted and characterized as part of 2013 GRASP,10 were
retrieved from STBRU. NG-MAST11 was performed on all isolates (see the
Supplementary Methods for culture and NG-MAST methodology).
Clinical specimens
This prospective diagnostic assessment was performed anonymized using
residual lysates derived from routine NAAT diagnosis that only allowed for
sample site and gender details to be collected. No details on identity, sex-
ual behaviour, age, ethnicity or other demographics were available to the
investigators and local research governance advised that a formal process
of ethics committee approval was not required for this study.
Clinical episodes of culture-positive N. gonorrhoeae infection at any
anatomical site from the Courtyard Genitourinary Medicine Clinic of SGH
in London, UK, over a 9 month period between 15 October 2012 and 18
July 2013, were identified. Residual NAAT samples derived from these epi-
sodes consisting of lysed specimens derived from the BD ProbeTec GC Qx
Amplified DNA Assay, performed on the Viper platform (Becton Dickinson,
Oxford, UK), were stored for 1 week at 48C for potential inclusion in the study.
Samples were eligible for inclusion if they came from the following
routinely encountered sites: vaginal, cervical, pharyngeal and rectal
swabs and urine specimens. Repeat clinical episodes from identical
patients were included if separated by ≥8 weeks from previous episodes.
Following meeting the inclusion criteria, the samples were anonymized so
that the only available data were anatomical site sampled and antimicro-
bial susceptibility profile of the N. gonorrhoeae cultured during the same
clinical attendance.
Antimicrobial susceptibility data for each clinically positive N. gonor-
rhoeae episode were obtained as part of routine diagnostic testing of
patients by the Department of Medical Microbiology, SGH. Susceptibility
data were recorded for the following antimicrobials: cefalexin, cefotaxime,
ciprofloxacin, nalidixic acid, penicillin, spectinomycin and tetracycline.
Testing was performed in accordance with BSAC methodology, with anti-
microbial susceptibility reported as susceptible, intermediate or resistant
depending on the disc diffusion zone diameter.12
Gonococcal nucleic acids were extracted from lysed NAAT samples by
centrifugation of 500 mL of residual sample at 20000 g for 5 min.
Following centrifugation, 250 mL of supernatant was removed and the
remaining liquid and pellet were used for total DNA extraction using the
PowerLyzerTM PowerSoilw DNA Isolation Kit according to the manufac-
turer’s instructions (MoBio, Carlsbad, CA, USA). DNA was eluted in a final
volume of 100 mL of nuclease-free water and stored at 2208C until add-
ition to real-time PCR reactions.
Statistical analysis
Results of NGSNP testing directly on residual N. gonorrhoeae-positive NAAT
lysates was compared with findings of routine culture-based AST. A sam-
ple size of 220 prospective clinical episodes was determined to be required
in order to assess the performance of NGSNP with 98% accuracy at a 95%
CI of 95%–100% (b¼80%, a¼0.05). CIs were calculated using a Wilson
score, assuming a binomial distribution, with MedCalc statistical software
(MedCalc, Ostend, Belgium). x2 tests were used to detect differences in the
failure rate of NGSNP and prevalence of ciprofloxacin resistance at different
sampling sites. Statistical analysis was performed using SPSS version 21
and MedCalc statistical software.
Results
Assay functionality was initially demonstrated by testing NGSNP
with genomic DNA extracted from a geographically diverse
panel of 23 ciprofloxacin-resistant N. gonorrhoeae isolates
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representing 22 NG-MAST types (see Table S2). The median cipro-
floxacin MIC for these isolates was 7 mg/L (IQR 4–32 mg/L). All
isolates included within this panel were successfully genotyped
as ‘resistant’ by the generation of a fluorescence signal within
the SNP detection (VIC) channel of the real-time PCR reaction.
The capacity of NGSNP was further verified using a panel of local
N. gonorrhoeae isolates, originally collected at SGH. NGSNP reac-
tions performed using genomic DNA extracted from these isolates
produced an SNP signal for all 18 (27%) demonstrated to be
phenotypically resistant to ciprofloxacin [median MIC of 16 mg/L
(IQR 8–16 mg/L)] and a WT signal for all remaining 49 phenotyp-
ically susceptible isolates. NG-MAST types were available for all 67
isolates and 40 different STs were observed (see Table S3).
Following successful validation, the diagnostic performance
of NGSNP was assessed using 290 NAAT specimens from 222 (56
female and 166 male) clinical episodes of culture-positive gonor-
rhoea that met the inclusion criteria during the study period
(Tables 1 and 2). Two female patients were sampled on two separ-
ate clinical episodes. Three male patients were sampled on two
separate clinical episodes and a single male patient provided sam-
ples attributable to four episodes. Repeat clinical episodes were
separated by a minimum of 8 weeks and a maximum of 8 months.
One hundred and seventy-four samples included in this study
were defined as genital (cervical, vaginal and urethral samples in
women and urethral swab and urine in men) and 116 samples
were defined as non-genital (throat or rectal swabs in males or
females). Some 99.4% of genital and 63.8% of non-genital
samples specimens had a positive N. gonorrhoeae culture from
the same sample site (see Tables 1 and 2). For this analysis,
cervical, vaginal and urethral samples in women and urethral
swab and urine samples in men were assumed to constitute the
same genital site.
Of the clinical episodes, 28.8% (64/222) were attributable to
the presence of ciprofloxacin-resistant N. gonorrhoeae in at least
one anatomical site (Table 3), with a higher proportion observed in
men compared with women [32.5% (54/166) versus 17.9%
(10/56); x2¼4.393, P¼0.04] and in non-genital sites compared
with genital sites [35.4% (35/99) versus 23.6% (29/123), respect-
ively; x2¼3.707, P¼0.054].
Multisite N. gonorrhoeae infection was observed in 71 (59 male
and 12 female) clinical episodes (Table 3). In three of these epi-
sodes (4.2%), all of which were in men, infection was attributable
to isolates with discordant ciprofloxacin susceptibility profiles
at different anatomical sites. Two patients possessed resistant
isolates in genital cultures whereas the remaining patient
was infected with a resistant isolate in their rectal culture; the
remaining infected sites in these patients were attributable to
ciprofloxacin-susceptible N. gonorrhoeae infection.
Total DNA was extracted from all residual sample lysates
included in the study and tested using NGSNP, yielding a result
in 90% (262/290) of samples (Tables 1 and 2). Failure (no ampli-
fication) of NGSNP was associated with non-genital sites com-
pared with genital samples (16.4% versus 5.2%; x2¼10.021,
P¼0.002) and a greater proportion of assay failures occurred in
samples in which culture results were derived from different sam-
ple sites (34.9% versus 5.3%; x2¼36.83, P,0.001).
Prior to determining the diagnostic performance of NGSNP, 28
samples were excluded from the final analysis due to assay
failure. Forty-three of the 290 samples were excluded from the
final analysis of NGSNP accuracy as susceptibility testing data
for these samples were not available from a matching anatomical
site (see Tables 1 and 2).
Where NAAT and phenotypic susceptibility sampling were
performed at the same site (Table 4), NGSNP demonstrated
Table 1. Distribution of NGSNP sample types and site used for corresponding AST: female samples (n¼69)
‘Genital’ ‘Non-genital’
NGSNP sample site [count]a cervical [33] vaginal [20 (3)] pharyngeal [12 (2)] rectal [4]
Susceptibility testing site cervical cervical urethral vaginal pharyngeal cervical rectal
Countb 33 (5) 17 (4) 2 (1) 1 10 (4) 2 4
aNumbers in parentheses represent the number of NGSNP assays that failed to yield a result.
bNumbers in parentheses represent the number of fluoroquinolone-resistant cultures of N. gonorrhoeae.
Table 2. Distribution of NGSNP sample types and site used for corresponding AST: male samples (n¼221)
‘Genital’ ‘Non-genital’
NGSNP sample site [count]a urine [121 (6)] pharyngeal [44 (9)] rectal [56 (8)]
Susceptibility testing site urethral pharyngeal urethral pharyngeal rectal urethral pharyngeal rectal
Countb 120 (39) 1 9 (2) 24 (8) 11 (3) 18 (6) 2 (2) 36 (12)
aNumbers in parentheses represent the number of NGSNP assays that failed to yield a result.
bNumbers in parentheses represent the number of fluoroquinolone-resistant cultures of N. gonorrhoeae.
N. gonorrhoeae ciprofloxacin susceptibility genotyping
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sensitivity and specificity for detecting ciprofloxacin susceptibility
of 95.8% (95% CI 91.5%–98.3%) and 100% (95% CI 94.7%–
100%), respectively. Therefore, absence of the SNP demonstrated
100% (95% CI 97.7%–100%) positive predictive value to predict
ciprofloxacin susceptibility of all culture-matched genital, pharyn-
geal and rectal samples (Table 4).
Discussion
NAATs have surpassed bacteriological culture as the primary
means of diagnosing N. gonorrhoeae infection,4,5 frequently
resulting in clinical management of gonorrhoea in the absence
of available antibiotic susceptibility data.6 In order to address
this deficiency in clinical practice, we developed and prospectively
evaluated a real-time PCR assay enabling genotypic detection of
gonococcal susceptibility to ciprofloxacin from residual NAAT
samples. This approach facilitated accurate prediction of gono-
coccal susceptibility to ciprofloxacin directly from residual genital
and non-genital patient samples. In patients diagnosed exclu-
sively by NAATs and recalled for treatment, prompt testing of
N. gonorrhoeae-positive samples using NGSNP would enable the
ciprofloxacin susceptibility status to be provided on the patient’s
return, aiding clinical management.
Use of a single 500 mg dose of ciprofloxacin has not been
recommended for empirically treating uncomplicated gonorrhoea
in the UK since 2002, when resistance rates increased beyond 5%,
rendering it unsuitable.13 However, as of 2013,.70% of N. gonor-
rhoeae isolates analysed by GRASP were susceptible to ciprofloxa-
cin,10 suggesting availability of susceptibility data would allow
almost 20000 of 29 000 cases of gonorrhoea diagnosed in
England and Wales in 2013 to include ciprofloxacin as a viable
treatment option.
We previously proposed that integration of genotypic markers
of AMR into NAATs and PoC tests may enable older antibiotics to be
used as effective treatments at diagnosis once again.14 The highly
specific nature of NGSNP and the genotypic assay underpinning it
has the potential for such integration, possibly with existing
NAATs.15 This would enable giving susceptibility-guided cipro-
floxacin therapy at PoC, either as monotherapy or as an adjunctive
component of combination therapy. Such personalized diagnos-
tics could serve to preserve the use of newer and future empirical
antigonococcal antibiotics such as extended-spectrum cephalos-
porins, gentamicin16 and solithromycin.17
Worldwide, the proportion of N. gonorrhoeae isolates identified
as ciprofloxacin susceptible from regional and national surveil-
lance programmes varies by geographic location. These estimates
include 29% –100% in Africa,18 52.9% in Europe,19 74.5% in
Table 3. Frequency of infected anatomical sites at patient’s clinical episode
Sample site
genital only pharyngeal only rectal only
genital and
pharyngeal
genital and
rectal
genital, rectal
and pharyngeal
rectal and
pharyngeal
Female episodes (n¼56) 42 (6) 1 1 9 (2) 0 3 (2) 0
Male episodes (n¼166) 81 (23a) 12 (3) 14 (6) 11 (4) 19 (9)b 11 (3) 18 (6)
Numbers in parentheses represent the number of cases attributable to a fluoroquinolone-resistant isolate of N. gonorrhoeae.
aA single male patient was infected with two strains of N. gonorrhoeae; this mixed infection was identified as one strain susceptible to tetracycline and
one strain resistant.
bAll patients with ciprofloxacin-resistant gonorrhoea had concordant phenotypic results at different sites except for three men with genital and rectal
cultures. In these men, there were two cases of rectal resistance and urethral susceptibility and one case of urethral resistance and rectal susceptibility.
Table 4. NGSNP assay performance for detection and prediction of ciprofloxacin susceptibility from genital and non-genital samples compared with
phenotypic susceptibility test from the same anatomical site
Episode type Sensitivity (%) Specificity (%)
Positive predictive
value (%)a
Negative predictive
value (%)b
Overall (n¼234) 95.8 (91.5–98.3) 100 (94.7–100) 100 (97.7–100) 90.7 (81.7–96.2)
female and male cases of urogenital infection (n¼164) 95.8 (90.4–98.6) 100 (92.3–100) 100 (96.8–100) 90.2 (78.6–96.7)
female cases (n¼50) 97.5 (86.8–99.9) 100 (69.2–100) 100 (91.0–100) 90.9 (58.7–99.8)
male cases (n¼114) 94.9 (87.4–98.6) 100 (90.3–100) 100 (95.1–100) 89.7 (76.3–97.2)
female and male cases of non-genital infection (n¼70) 95.8 (85.8–99.5) 100 (84.6–100) 100 (92.3–100) 91.7 (73.0–99.0)
female and male cases of pharyngeal infection (n¼30) 100 (82.4–100) 100 (71.5–100) 100 (82.4–100) 100 (71.5–100)
female and male cases of rectal infection (n¼40) 93.1 (77.2–99.2) 100 (71.5–100) 100 (87.2–100) 84.6 (54.6–98.1)
Numbers in parentheses are the 95% CIs. Performance was evaluated on those in which the assay was successful (see Tables 1 and 2 for total number of
cases and tests). Test positivity is defined as the absence of the serine 91 to phenylalanine mutation.
aThis value represents the predictive value of the absence of the mutation for ciprofloxacin susceptibility.
bThis value represents the predictive value of the presence of the mutation for ciprofloxacin resistance.
Pond et al.
900
 at St G
eorge's Library on A
pril 20, 2016
http://jac.oxfordjournals.org/
D
ow
nloaded from
 
Russia,20 86.5% in the USA,21 57.9% in South America and the
Caribbean,22 0%–62% of isolates in South-East Asia Region23
and 1%–100% in the Western Pacific,24 indicating the potential
global utility of such an approach.
Validation of NGSNP performance on phylogenetically diverse
isolates was a clear strength of the study, indicating applicability
of the selected gyrA marker of resistance beyond our local popu-
lation. We have conducted a review of published studies, which
suggests that a residue change at codon 96 of GyrA occurs in
96% of ciprofloxacin-resistant strains of N. gonorrhoeae (C. L.
Hall, M. J. Pond, E. Harding-Esch, S. T. Sadiq, unpublished data),
though we also note intermediate susceptibility to ciprofloxacin
may occur in isolates with alterations at codon 95 of GyrA
alone.25 In addition to SNPs within gyrA, resistant isolates may
demonstrate additional genomic changes that give rise to residue
changes at codons 86 aspartate, 87 serine, 88 serine and 91 glu-
tamate of ParC.26 Inclusion of these genomic markers in a future
assay design may improve assay sensitivity for the detection of
susceptible gonococcal infections. The presence of other inde-
pendent markers27,28 of ciprofloxacin resistance noted in other
bacterial species demonstrates the need for continuing pheno-
typic/genotypic surveillance29 to inform genotypic susceptibility
assays.
This study highlighted an additional complication of utilizing
NAATs for N. gonorrhoeae infection, namely the reduction in
assay success observed when diagnosing non-genital infec-
tion.9 NGSNP assay failure occurred more frequently in extrage-
nital NAAT-positive samples. At the time of this study,
non-genital NAAT-positive specimens were not confirmed with
a secondary NAAT assay if patients were culture positive at an
additional site.
Interestingly, among non-genital samples excluded from
analysis due to susceptibility testing data derived from a non-
matching anatomical site, a decline in NGSNP test performance
was observed. Although this finding may be attributable to
NAAT false positivity,9 the possibility of infection with N. gonor-
rhoeae clones of discordant antimicrobial susceptibility at each
anatomical site cannot be excluded.
This hypothesis is strengthened by the observation that three
men were indeed infected with isolates possessing different
antimicrobial susceptibility profiles at separate anatomical sites
simultaneously. Furthermore, a single case of mixed gonococcal
infection within a case of male urethral infection (see Table 3)
was observed, though both isolates were resistant to ciprofloxacin
and did not affect the assay under analysis.
These observations suggest a requirement for multisite testing
when deploying genotypic resistance susceptibility testing for
gonorrhoea and that present culture techniques may underdetect
mixed N. gonorrhoeae infection.30,31 Accurately quantifying rates
at which mixed gonococcal infection occurs within anatomical
sites and within patients will improve both molecular and conven-
tional methods of susceptibility testing.
In conclusion, NGSNP affords highly accurate genotypic pre-
diction of gonococcal ciprofloxacin from routine clinical samples
of different anatomical sites, demonstrating that provision of
susceptibility data in the absence of culture is feasible. This
approach may serve to enhance current empirical treatment
regimens and spare the use of newer antibiotics, providing an
additional pragmatic approach to address the spread of MDR
gonorrhoea.
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